Lasa Supergenerics Share Price | Lasa Supergenerics Stock Screener
LASA
Pharmaceuticals
Share Price NSE
₹7.13
▲
0.02 (0.28%)
Share Price BSE
₹7.12
▼
-0.03 (-0.42%)
As of July 20, 2026, the Lasa Supergenerics share price (NSE: LASA) is ₹7.13 on NSE and ₹7.12 on BSE, up 0.28% from the previous close, with shares trading between ₹7.12 and ₹7.33, and a 52-week range of ₹5.67–₹14.01.
Analyse Lasa Supergenerics share price performance and track historical price performance.
Use the Lasa Supergenerics stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Lasa Supergenerics Market Cap
₹36.82 Cr.
LASA P/E Ratio (TTM)
-1.08
Lasa Supergenerics P/B Ratio
0.74
EPS (TTM)
₹-6.80
Dividend Yield
-
Debt to Equity
0.13
LASA 52 Week High
₹14.01
Lasa Supergenerics 52 Week Low
₹5.67
Operating Margin
-113.00%
Profit Margin
-140.00%
LASA Revenue (TTM)
₹25.00
EBITDA
₹-28.00
Net Income
₹-35.00
Total Assets
₹102.00
Total Equity
₹84.00
Lasa Supergenerics Share Price Chart
Screen Lasa Supergenerics share price with an interactive chart. Analyse LASA price trends and volatility across different timeframes.
Lasa Supergenerics Company Profile - Fundamental Screener
Screen Lasa Supergenerics company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for LASA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE670X01014
Lasa Supergenerics Balance Sheet Screener
Screen LASA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 102 | 151 | 164 | 209 | 208 | 232 | 259 | 287 | 228 | 0 |
| Current Assets | 33 | 38 | 39 | 66 | 64 | 76 | 86 | 109 | 79 | 0 |
| Fixed Assets | 68 | 110 | 119 | 137 | 143 | 152 | 162 | 170 | 119 | 0 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1 | 5 | 3 | 7 | 8 | 15 | 46 | 62 | 83 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 84 | 97 | 118 | 158 | 159 | 142 | 105 | 117 | 76 | 0 |
| Share Capital | 50 | 50 | 50 | 50 | 41 | 41 | 23 | 23 | 0 | 0 |
| Reserves & Surplus | 32 | 47 | 68 | 108 | 118 | 101 | 82 | 95 | 75 | 0 |
Lasa Supergenerics Income Statement Screener - Profit & Revenue Analysis
Screen Lasa Supergenerics income statement and profit fundamentals.
Analyze LASA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Lasa Supergenerics share price evaluation.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25 | 148 | 104 | 131 | 137 | 202 | 168 | 170 | 247 | 201 | 0 |
| Expenses | 54 | 136 | 102 | 136 | 121 | 155 | 137 | 159 | 202 | 153 | 0 |
| EBITDA | -28 | 11 | 2 | -5 | 16 | 47 | 30 | 12 | 45 | 48 | 0 |
| Operating Profit % | -113.00% | 4.00% | 2.00% | -5.00% | 12.00% | 23.00% | 18.00% | 7.00% | 17.00% | 23.00% | 0.00% |
| Depreciation | 6 | 12 | 11 | 13 | 15 | 16 | 17 | 19 | 18 | 8 | 0 |
| Interest | 0 | 3 | 2 | 4 | 0 | 2 | 8 | 8 | 11 | 12 | 0 |
| Profit Before Tax | -35 | -19 | -19 | -42 | -6 | 30 | 5 | -16 | 15 | 2 | 0 |
| Tax | 0 | -5 | 3 | -4 | -1 | 7 | 1 | -4 | 3 | 0 | 0 |
| Net Profit | -35 | -15 | -22 | -39 | -5 | 23 | 4 | -12 | 12 | 2 | 0 |
| EPS | -6.80 | -2.95 | -4.34 | -7.71 | -1.06 | 5.60 | 0.89 | -5.26 | 5.43 | 1.15 | 0.00 |
Lasa Supergenerics Cash Flow Screener - Liquidity Fundamentals
Screen LASA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -3 | 2 | -17 | 9 | 41 | 14 | 41 | 40 | -3 | 0 |
| Investing Activities | 8 | 0 | 11 | -3 | -4 | -2 | -7 | -44 | 0 | 0 |
| Financing Activities | -6 | -2 | -4 | 0 | -36 | -10 | -33 | 4 | 0 | 0 |
| Net Cash Flow | 0 | 0 | -10 | 6 | 1 | 2 | 0 | 0 | -3 | 0 |
Lasa Supergenerics Shareholding Pattern Screener
See Lasa Supergenerics shareholding pattern with promoter, FII, and DII holdings.
Check Lasa Supergenerics promoter holding and ownership changes for LASA on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.12% | 0.00% | 0.01% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 42.04% | 34.08% | 34.08% | 42.14% | 42.04% | 34.15% | 34.24% | 34.08% |
| Other Holding | 4.31% | 12.27% | 12.27% | 4.21% | 4.31% | 12.08% | 12.11% | 12.26% |
| Shareholder Count | 27,702 | 27,188 | 27,188 | 28,656 | 28,120 | 27,615 | 27,217 | 27,969 |
Lasa Supergenerics Share Dividend Screener - Share Yield Analysis
Check Lasa Supergenerics dividend history with payout and yield data.
View Lasa Supergenerics dividend details including ex-dates and amounts for LASA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.25 | 1.38% |
| 2021-March | ₹0.25 | 0.60% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Lasa Supergenerics Stock Index Membership
See which indices include Lasa Supergenerics stock.
Check LASA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Lasa Supergenerics Market Events Screener - Corporate Actions
Get Lasa Supergenerics corporate actions including splits, bonuses, and buybacks.
Check Lasa Supergenerics stock events that may affect LASA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 5.05% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | -5.63% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -6.51% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | 32.84% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 1.95% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | -12.30% |
| 2025-02-22 | 2025-02-22 | Extraordinary General Meeting | NA | -7.24% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -4.53% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -7.89% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | -2.28% |
| 2022-09-16 | 2022-09-19 | Dividend | ₹ 0.25 /share | -32.02% |
| 2021-09-15 | 2021-09-17 | Dividend | ₹ 0.25 /share | -6.54% |
Lasa Supergenerics Competitors Screener - Peer Comparison
Screen LASA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 465,831 | 40.11 | 61,674 | 12.69% | 11,565 | 64.42 |
| Divis Laboratories | 190,062 | 71.68 | 10,560 | 8.73% | 2,520 | 62.61 |
| Torrent Pharmaceuticals | 168,133 | 78.32 | 13,886 | 20.34% | 2,138 | 78.08 |
| Cipla | 116,443 | 29.85 | 29,045 | 2.24% | 3,870 | 51.98 |
| Zydus Life Science | 114,037 | 22.02 | 27,658 | 17.64% | 5,026 | 58.18 |
| Lupin | 112,941 | 21.32 | 27,488 | 19.98% | 5,345 | 67.70 |
| Mankind Pharma | 104,488 | 53.47 | 14,278 | 12.03% | 1,750 | 55.47 |
| Dr Reddys Laboratories | 104,108 | 24.79 | 35,059 | 3.90% | 4,158 | 34.07 |
| Aurobindo Pharma | 89,161 | 25.69 | 33,385 | 3.21% | 3,376 | 54.05 |
| Laurus Labs | 84,347 | 94.51 | 6,868 | 22.01% | 890 | 66.92 |
Lasa Supergenerics Company Announcements - News Screener
Screen LASA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-06-29 | Closure of Trading Window | - |
| 2026-05-30 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-29 | Integrated Filing As On March 31 2026 | - |
| 2026-05-29 | Related Party Transaction As On 31St March 2026 | - |
| 2026-05-29 | Board Meeting Outcome for Revised Outcome Of Board Meeting For Quarter Ended 31 March 2026 | - |
| 2026-05-29 | Board Meeting Outcome for Outcome Of Board Meeting For Quarter Ended March 31 St 2026 | - |
| 2026-05-19 | Board Meeting Intimation for Quarter And Year Ended March 31St 2026 | - |
| 2026-05-12 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-16 | Declaration With Respect To Non -Applicability Of Large Entities | - |
| 2026-03-30 | Closure of Trading Window | - |
| 2026-02-13 | Integrated Filing For Quarter Ended December 31 2025 | - |
| 2026-02-13 | Results For Quarter Ended 31St December 2025 | - |
| 2026-02-13 | Board Meeting Outcome for Outcome Of Board Meeting For Quarter Ended 31St December 2025 | - |
| 2026-02-03 | Board Meeting Intimation for For The Quarter Ended December 31 2025 | - |
| 2026-01-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-01-02 | Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. January 02 2026 1. Appointment Of Mr. Ganesh Suresh Potdar As An Additional Director In Capacity Of (Executive Director) And Occupier Of All Units Of The Company. | - |
| 2025-12-29 | Closure of Trading Window | - |
| 2025-12-15 | Appointment of Company Secretary and Compliance Officer | - |
| 2025-12-11 | Announcement under Regulation 30 (LODR)-Cessation | - |
| 2025-11-14 | Related Party Trasnaction As 30.09.2025 | - |